Results 1 to 10 of about 13,727 (197)
Efficacy and safety of sacubitril/valsartan in end-stage renal disease patients with heart failure: a review [PDF]
Annals of MedicinePurpose End-stage renal disease (ESRD) is associated with a heavy global public health burden and an increased risk of cardiovascular diseases. Sacubitril/valsartan has been shown to improve cardiovascular outcomes in patients with heart failure and ...
Peiyun Li, Yupei Li, Ling Zhang
doaj +2 more sources
Frontiers in Pharmacology, 2022 Clinical use of the combination therapy of the neprilysin inhibitor sacubitril and angiotensin II type 1 receptor blocker valsartan is known to be associated with albuminuria.
Elizabeth Alana Gray +3 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2023 IntroductionIn 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from ...
Pei Yang +7 more
doaj +1 more source
Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
Frontiers in Endocrinology, 2022 Treatment of heart failure with the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan improved glycemic control in individuals with type 2 diabetes. The relative contribution of neprilysin inhibition versus angiotensin II receptor antagonism
Nathalie Esser +17 more
doaj +1 more source
Bradykinin-Mediated Angioedema Induced by Commonly Used Cardiovascular Drugs
Drugs and Drug Candidates, 2023 ACE inhibitors, sartans, and sacubitril are among the most important drugs for the prevention of cardiovascular mortality and morbidity. At the same time, they are known to cause non-allergic bradykinin-mediated angioedema, a potentially fatal swelling ...
Janina Hahn +3 more
doaj +1 more source
What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
Journal of Cardiovascular Development and Disease, 2022 Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the ...
Hisham A. Badreldin +8 more
doaj +1 more source
"Primum non nocere (First, do no harm)". Case report
Кардиоваскулярная терапия и профилактика, 2023 Diastolic myocardial dysfunction is the most important pathogenetic factor in heart failure and makes a significant contribution to hemodynamic disorders, which leads to a significant deterioration in the quality of life and prognosis of patients.
D. A. Nefedova +2 more
doaj +1 more source
Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
Frontiers in Pharmacology, 2022 Cardiovascular diseases have become a major clinical burden globally. Heart failure is one of the diseases that commonly emanates from progressive uncontrolled hypertension. This gives rise to the need for a new treatment for the disease.
Nor Hidayah Mustafa +5 more
doaj +1 more source
Archives of Pharmaceutical Sciences Ain Shams University, 2023 One of the leading causes of illness and mortality worldwide is cardiovascular disease. The optimum therapy in the majority of cases is accomplished by combining a number of medications, each of which has a unique mechanism of action, to treat ...
Ragaa Magdy +3 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Objectives: Although the PARAGON-HF trial failed to reach its primary endpoint, subgroups of patients with heart failure with preserved ejection fraction (HFpEF) still appear to benefit from Sacubitril/Valsartan therapy.
Christof Burgdorf +4 more
doaj +1 more source